Leap Therapeutics (LPTX) Competitors $0.29 -0.01 (-2.80%) Closing price 04:00 PM EasternExtended Trading$0.30 +0.01 (+2.43%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. IMMX, VHAQ, ANRO, ACHL, RPTX, ASRT, CRVO, QNCX, RENB, and VTGNShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Immix Biopharma (IMMX), Viveon Health Acquisition (VHAQ), Alto Neuroscience (ANRO), Achilles Therapeutics (ACHL), Repare Therapeutics (RPTX), Assertio (ASRT), CervoMed (CRVO), Quince Therapeutics (QNCX), Renovaro (RENB), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Immix Biopharma Viveon Health Acquisition Alto Neuroscience Achilles Therapeutics Repare Therapeutics Assertio CervoMed Quince Therapeutics Renovaro VistaGen Therapeutics Leap Therapeutics (NASDAQ:LPTX) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Is LPTX or IMMX more profitable? Immix Biopharma's return on equity of -130.02% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -162.15% -120.05% Immix Biopharma N/A -130.02%-86.33% Do analysts rate LPTX or IMMX? Leap Therapeutics presently has a consensus target price of $3.38, indicating a potential upside of 1,071.88%. Immix Biopharma has a consensus target price of $7.00, indicating a potential upside of 190.46%. Given Leap Therapeutics' higher possible upside, equities research analysts plainly believe Leap Therapeutics is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in LPTX or IMMX? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, LPTX or IMMX? Leap Therapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Which has stronger earnings and valuation, LPTX or IMMX? Immix Biopharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.70-0.17Immix BiopharmaN/AN/A-$21.61M-$0.70-3.44 Does the media refer more to LPTX or IMMX? In the previous week, Immix Biopharma had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 1 mentions for Immix Biopharma and 0 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Immix Biopharma's score of 0.94 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Very Positive Immix Biopharma Positive SummaryImmix Biopharma beats Leap Therapeutics on 9 of the 13 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.28M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.1721.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book0.327.518.055.38Net Income-$67.56M-$55.05M$3.15B$248.50M7 Day Performance2.86%2.45%1.85%2.97%1 Month Performance-19.67%7.33%4.81%6.02%1 Year Performance-82.96%5.38%34.86%20.39% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.3 of 5 stars$0.29-2.8%$3.38+1,071.9%-84.2%$12.28MN/A-0.1740Positive NewsGap DownIMMXImmix Biopharma3.6778 of 5 stars$2.23-0.4%$7.00+213.9%+3.3%$62.44MN/A-3.199VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeANROAlto Neuroscience2.3506 of 5 stars$2.37+5.1%$8.50+259.4%-80.5%$60.91MN/A0.00N/ANews CoverageACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250RPTXRepare Therapeutics2.5022 of 5 stars$1.41flat$4.50+219.1%-57.4%$60.48M$53.48M-0.47180Positive NewsASRTAssertio1.7563 of 5 stars$0.63+0.3%$2.75+335.7%-46.1%$60.26M$124.96M-1.9720CRVOCervoMed3.3958 of 5 stars$6.52-4.8%$27.63+323.7%-63.2%$59.61M$9.74M0.004News CoverageQNCXQuince Therapeutics3.3036 of 5 stars$1.32+1.5%$8.00+506.1%+109.7%$59.11MN/A-0.9560Positive NewsRENBRenovaro1.1848 of 5 stars$0.37+7.9%N/A-82.6%$58.76MN/A0.0020News CoverageHigh Trading VolumeVTGNVistaGen Therapeutics1.8123 of 5 stars$1.96-2.0%N/A-43.7%$58.31M$490K-1.1840 Related Companies and Tools Related Companies Immix Biopharma Alternatives Viveon Health Acquisition Alternatives Alto Neuroscience Alternatives Achilles Therapeutics Alternatives Repare Therapeutics Alternatives Assertio Alternatives CervoMed Alternatives Quince Therapeutics Alternatives Renovaro Alternatives VistaGen Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
